drugset / Trial / NCT04885998
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
Non-randomizedSequentialOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.
Timeline
- Start
- 2021-09-27
- Primary completion
- 2023-07-12
- Completion
- 2024-09-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMG 404 | Monoclonal antibody | — | Intravenous |
| Subject | Tarlatamab | Protein / enzyme biologic | — | Intravenous |